Last $40.45 USD
Change Today +0.16 / 0.40%
Volume 636.9K
IPXL On Other Exchanges
Symbol
Exchange
NASDAQ GS
As of 5:20 PM 03/2/15 All times are local (Market data is delayed by at least 15 minutes).

impax laboratories inc (IPXL) Snapshot

Open
$40.15
Previous Close
$40.29
Day High
$40.50
Day Low
$39.91
52 Week High
02/23/15 - $41.39
52 Week Low
08/4/14 - $22.12
Market Cap
2.9B
Average Volume 10 Days
631.7K
EPS TTM
$1.07
Shares Outstanding
71.3M
EX-Date
--
P/E TM
37.9x
Dividend
--
Dividend Yield
--
Current Stock Chart for IMPAX LABORATORIES INC (IPXL)

impax laboratories inc (IPXL) Related Businessweek News

No Related Businessweek News Found

impax laboratories inc (IPXL) Details

Impax Laboratories, Inc., a specialty pharmaceutical company, develops, manufactures, and markets bioequivalent pharmaceutical products. It operates in two segments, Global Pharmaceuticals Division and Impax Pharmaceuticals Division. The Global Pharmaceuticals Division provides generic pharmaceutical products through its global products sales channel directly to wholesalers, large retail drug chains, and others; generic prescription products through third-party pharmaceutical entities to alliance and collaboration agreements; generic pharmaceutical over-the-counter (OTC) and prescription products to third parties; and generic pharmaceutical OTC products through third-party pharmaceutical companies. The Impax Pharmaceutical Division focuses on the development and promotion through its specialty sales force of proprietary brand pharmaceutical products for the treatment of central nervous system disorders, including migraine, multiple sclerosis, Parkinson’s disease, and postherpetic neuralgia. The company markets and sells its products to drug wholesalers, warehousing chain drug stores, mass merchandisers, and mail-order pharmacies in the continental United States and the Commonwealth of Puerto Rico. Impax Laboratories, Inc. has a strategic alliance agreement with Teva Pharmaceuticals Curacao N.V to develop, manufacture, and distribute controlled release generic pharmaceutical products. The company was founded in 1993 and is headquartered in Hayward, California.

1,061 Employees
Last Reported Date: 02/26/15
Founded in 1993

impax laboratories inc (IPXL) Top Compensated Officers

Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $385.0K
President of Impax Pharmaceuticals Division
Total Annual Compensation: $500.5K
Senior Vice President, General Counsel and Se...
Total Annual Compensation: $470.2K
Compensation as of Fiscal Year 2013.

impax laboratories inc (IPXL) Key Developments

Impax Laboratories Inc. Reports Unaudited Consolidated Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2014

Impax Laboratories Inc. reported unaudited consolidated earnings results for the fourth quarter and full year ended December 31, 2014. For the quarter, the company reported total revenues of $131,211,000 compared to $100,741,000 for the same period a year ago. Profit from operations was $1,154,000 compared to loss of $16,234,000 for the same period a year ago. Income before income taxes was $1,650,000 compared to loss before income taxes of $15,835,000 for the same period a year ago. Net income was $120,000 or nil per diluted share compared to net loss of $9,622,000 or $0.14 diluted loss per share for the same period a year ago. Adjusted net income was $11,033,000 or $0.16 per diluted share compared to adjusted net loss of $1,641,000 or $0.02 per diluted share for the same period a year ago. Adjusted EBITDA was $27,431,000 compared to $1,639,000 for the same period a year ago. EBITDA was $7,225,000 compared to negative EBITDA of $12,605,000 for the same period a year ago. For the year, the company reported total revenues of $596,049,000 compared to $511,502,000 for the same period a year ago. Profit from operations was $88,816,000 compared to loss of $6,387,000 for the same period a year ago. Income before income taxes was $90,559,000 compared to income of $146,940,000 for the same period a year ago. Net income was $57,353,000 or $0.81 per diluted share compared to net income of $101,259,000 or $1.47 per diluted share for the same period a year ago. Net cash provided by operating activities was $32,817,000 compared to $149,940,000 for the same period a year ago. Purchases of property, plant and equipment were of $29,913,000 compared to $32,785,000 for the same period a year ago. Adjusted net income was $93,205,000 or $1.32 per diluted share compared to adjusted net income of $56,112,000 or $0.82 per diluted share for the same period a year ago. EBITDA was $112,073,000 compared to $165,692,000 for the same period a year ago. Adjusted EBITDA was $186,671,000 compared to $115,420,000 for the same period a year ago.

Impax Laboratories Inc. to Report Q4, 2014 Results on Feb 24, 2015

Impax Laboratories Inc. announced that they will report Q4, 2014 results at 8:30 AM, US Eastern Standard Time on Feb 24, 2015

Impax Laboratories Inc., Q4 2014 Earnings Call, Feb 24, 2015

Impax Laboratories Inc., Q4 2014 Earnings Call, Feb 24, 2015

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
IPXL:US $40.45 USD +0.16

IPXL Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Acorda Therapeutics Inc $35.01 USD +1.17
BTG PLC 747.00 GBp -11.50
Depomed Inc $23.06 USD +1.11
Glenmark Pharmaceuticals Ltd 786.85 INR -3.05
Lannett Co Inc $62.92 USD +0.52
View Industry Companies
 

Industry Analysis

IPXL

Industry Average

Valuation IPXL Industry Range
Price/Earnings 49.5x
Price/Sales 4.6x
Price/Book 3.1x
Price/Cash Flow 50.1x
TEV/Sales 4.1x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact IMPAX LABORATORIES INC, please visit www.impaxlabs.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.